Evidence map›Paper›PMID 39180719›Full record

ArticleJapanese journal of clinical oncology2024

Association of stromal type IV collagen and prognosis in neoadjuvant chemotherapy-treated pancreatic cancer.

Yasuhiro Nakamura, Takehiro Yasukawa, Yuki Fukumura, Yoshinori Takeda, Hiroshi Imamura, Yang Shi, Mu Li, Masaaki Abe, Saya Uyama, Kazunori Kajino and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Japanese journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. The Duality of Collagens in Metastases of Solid Tumors.International journal of molecular sciences · 2025
    Review
  4. Collagen IV biosynthesis: Intracellular choreography of post-translational modifications.Matrix biology : journal of the International Society for Matrix Biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yasuhiro NakamuraDepartment of Orthopaedics, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Takehiro YasukawaDepartment of Molecular Pathogenesis, Juntendo University Graduate School of Medicine, Tokyo, Japan.ORCID 0000-0001-9531-8780
Yuki FukumuraDepartment of Human Pathology, Juntendo University School of Medicine, Tokyo, Japan.
Yoshinori TakedaDepartment of Hepatobiliary and Pancreatic Surgery, Juntendo University School of Medicine, Tokyo Japan.ORCID 0000-0002-1512-1687
Hiroshi ImamuraDepartment of Hepatobiliary and Pancreatic Surgery, Juntendo University School of Medicine, Tokyo Japan.
Yang ShiDepartment of Molecular Pathogenesis, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Mu LiDepartment of Molecular Pathogenesis, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Masaaki AbeDepartment of Pathology and Oncology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Saya UyamaDepartment of Pathology and Oncology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Kazunori KajinoDepartment of Human Pathology, Juntendo University School of Medicine, Tokyo, Japan.
Muneaki IshijimaDepartment of Orthopaedics, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Akio SaiuraDepartment of Hepatobiliary and Pancreatic Surgery, Juntendo University School of Medicine, Tokyo Japan.
Akira OrimoDepartment of Molecular Pathogenesis, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Funding

Japan Society for the Promotion of Science 21 K07127Juntendo University School of Medicine Project grantOkinaka Memorial Institute for Medical ResearchRenee Medical Corporation
6 · The paper itself

Abstract

backgroundPancreatic ductal adenocarcinoma (PDAC) has poor prognosis due to its low surgical eligibility and resistance to chemotherapy. Abundant stroma is characteristic of PDAC, and cancer-associated fibroblasts (CAFs) are a major stromal constituent, contributing to chemoresistance. Because neoadjuvant chemotherapy (NAC) is included in PDAC treatment as a standard regimen, the role of CAFs in NAC resistance must be studied. Although type IV collagen (COLIV) is present in the tumor of PDAC, the association between COLIV and disease advancement of NAC-treated PDAC is unclear.

methodsUsing a cohort of NAC-treated patients with PDAC, we examined clinicopathological data and conducted immunohistochemical analysis of COLIV in tissue specimens prepared from surgically resected pancreas. RESULTS AND

conclusionsOur analysis revealed that ~50% of the cases were positive for COLIV in the stroma and diffuse COLIV staining was an independent poor prognosis factor alongside high serum CA19-9 before NAC treatment (>37 U/mL) and postsurgical residual tumors. Based on these findings, we propose that stromal COLIV staining can be used to predict prognosis in NAC-treated patients with PDAC after surgery. Additionally, these findings suggest a possibility that stromal COLIV staining indicates resistance to anticancer drugs and/or contributes to malignancy in PDAC.

Indexed as

Carcinoma, Pancreatic DuctalCollagen Type IVNeoadjuvant TherapyPancreatic NeoplasmsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCancer-Associated FibroblastsChemotherapy, AdjuvantFemaleHumansMaleMiddle AgedPrognosisStromal CellsCollagen Type IVcancer-associated fibroblastsneoadjuvant chemotherapypancreatic ductal adenocarcinomastromatype IV collagen

Identifiers

PMID39180719
PMCPMC11631120

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.